Antibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN1107849 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Interleukin 4 (IL4) antibody
- Antibody type
- Monoclonal
- Description
- Ion exchange chromatography
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- B-S4
- Vial size
- 0.5 mg
- Storage
- Store the antibody undiluted at 2-8°C.
Submitted references Synergistic induction of antigen-specific CTL by fusions of TLR-stimulated dendritic cells and heat-stressed tumor cells.
Streptococcal preparation OK-432 promotes fusion efficiency and enhances induction of antigen-specific CTL by fusions of dendritic cells and colorectal cancer cells.
Human CD4+CD25+ regulatory T lymphocytes inhibit lipopolysaccharide-induced monocyte survival through a Fas/Fas ligand-dependent mechanism.
Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells.
Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins.
Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10.
Koido S, Hara E, Homma S, Mitsunaga M, Takahara A, Nagasaki E, Kawahara H, Watanabe M, Toyama Y, Yanagisawa S, Kobayashi S, Yanaga K, Fujise K, Gong J, Tajiri H
Journal of immunology (Baltimore, Md. : 1950) 2007 Oct 1;179(7):4874-83
Journal of immunology (Baltimore, Md. : 1950) 2007 Oct 1;179(7):4874-83
Streptococcal preparation OK-432 promotes fusion efficiency and enhances induction of antigen-specific CTL by fusions of dendritic cells and colorectal cancer cells.
Koido S, Hara E, Homma S, Torii A, Mitsunaga M, Yanagisawa S, Toyama Y, Kawahara H, Watanabe M, Yoshida S, Kobayashi S, Yanaga K, Fujise K, Tajiri H
Journal of immunology (Baltimore, Md. : 1950) 2007 Jan 1;178(1):613-22
Journal of immunology (Baltimore, Md. : 1950) 2007 Jan 1;178(1):613-22
Human CD4+CD25+ regulatory T lymphocytes inhibit lipopolysaccharide-induced monocyte survival through a Fas/Fas ligand-dependent mechanism.
Venet F, Pachot A, Debard AL, Bohe J, Bienvenu J, Lepape A, Powell WS, Monneret G
Journal of immunology (Baltimore, Md. : 1950) 2006 Nov 1;177(9):6540-7
Journal of immunology (Baltimore, Md. : 1950) 2006 Nov 1;177(9):6540-7
Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells.
Todaro M, Zerilli M, Ricci-Vitiani L, Bini M, Perez Alea M, Maria Florena A, Miceli L, Condorelli G, Bonventre S, Di Gesù G, De Maria R, Stassi G
Cancer research 2006 Feb 1;66(3):1491-9
Cancer research 2006 Feb 1;66(3):1491-9
Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
Koido S, Hara E, Homma S, Torii A, Toyama Y, Kawahara H, Watanabe M, Yanaga K, Fujise K, Tajiri H, Gong J, Toda G
Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Nov 1;11(21):7891-900
Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Nov 1;11(21):7891-900
IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins.
Conticello C, Pedini F, Zeuner A, Patti M, Zerilli M, Stassi G, Messina A, Peschle C, De Maria R
Journal of immunology (Baltimore, Md. : 1950) 2004 May 1;172(9):5467-77
Journal of immunology (Baltimore, Md. : 1950) 2004 May 1;172(9):5467-77
Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10.
Stassi G, Todaro M, Zerilli M, Ricci-Vitiani L, Di Liberto D, Patti M, Florena A, Di Gaudio F, Di Gesù G, De Maria R
Cancer research 2003 Oct 15;63(20):6784-90
Cancer research 2003 Oct 15;63(20):6784-90
No comments: Submit comment
No validations: Submit validation data